Biodexa Pharmaceuticals Plc (BDRX) ADR Each Representing 10000 Ord Shares SPON

Sell:$0.86Buy:$0.89$0.02 (2.26%)

Prices delayed by at least 15 minutes
Sell:$0.86
Buy:$0.89
Change:$0.02 (2.26%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.86
Buy:$0.89
Change:$0.02 (2.26%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

Key people

Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Dmitry Zamoryakhin
Chief Scientific Officer, Chief Medical Officer
Daniel Palmer
Vice President - Technology
Nicola Tuckwell
Vice President, Head of Clinical Operations
Fiona Sharp
Group Controller
Steve Ellul
Chief Business Officer
Gary A. Shangold
Chief Medical Officer
Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Sijmen De Vries
Non-Executive Independent Director
Ann Merchant
Non-Executive Independent Director
Simon Turton
Senior Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    BDRX
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US59564R8079
  • Market cap
    $4.44m
  • Employees
    13
  • Shares in issue
    145.04m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.